Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Lewis, L. Hunsicker, W. Clarke, T. Berl, M. Pohl, J. Lewis, E. Ritz, R. Atkins, R. Rohde, I. Raz (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.The New England journal of medicine, 345 12
W. Nelson (1969)
Hazard Plotting for Incomplete Failure DataJournal of Quality Technology, 1
P. Ruggenenti, A. Perna, Giulia Gherardi, G. Garini, Carmine Zoccali, M. Salvadori, F. Scolari, F. Schena, G. Remuzzi (1999)
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuriaThe Lancet, 354
L. Einhorn, M. Zhan, V. Hsu, Lori Walker, Maureen Moen, S. Seliger, M. Weir, J. Fink (2009)
The frequency of hyperkalemia and its significance in chronic kidney disease.Archives of internal medicine, 169 12
L. Moist, F. Port, S. Orzol, E. Young, Truls Østbye, R. Wolfe, T. Hulbert-Shearon, C. Jones, W. Bloembergen (2000)
Predictors of loss of residual renal function among new dialysis patients.Journal of the American Society of Nephrology : JASN, 11 3
Kjell Benson, A. Hartz (2000)
A comparison of observational studies and randomized, controlled trialsAmerican journal of ophthalmology, 130 5
Tsung-Mei Cheng (2003)
Taiwan's new national health insurance program: genesis and experience so far.Health affairs, 22 3
A. Greenberg (2005)
Primer on Kidney Diseases
Hiromichi Suzuki, Y. Kanno, S. Sugahara, H. Okada, H. Nakamoto (2004)
Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD.American journal of kidney diseases : the official journal of the National Kidney Foundation, 43 6
(1997)
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy., 349
G. Bakris, M. Siomos, D. Richardson, I. Janssen, W. Bolton, L. Hebert, R. Agarwal, D. Catanzaro (2000)
ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.Kidney international, 58 5
F. Hou, Xun Zhang, G. Zhang, D. Xie, Ping-yan Chen, Wei Zhang, Jian-ping Jiang, M. Liang, G. Wang, Zheng-rong Liu, Ren Geng (2006)
Efficacy and safety of benazepril for advanced chronic renal insufficiency.The New England journal of medicine, 354 2
Sanjeev Baweja, S. Holt, L. McMahon (2010)
The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 26 5
G. Montalescot, J. Collet (2005)
Preserving cardiac function in the hypertensive patient: why renal parameters hold the key.European heart journal, 26 24
PK Li, KM Chow, TY Wong, CB Leung, CC Szeto (2003)
Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis: a randomized, controlled study., 139
R. Foley, Anne Murray, Shuling Li, C. Herzog, A. McBean, P. Eggers, A. Collins (2005)
Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999.Journal of the American Society of Nephrology : JASN, 16 2
L. Iezzoni (1994)
Risk Adjustment for Measuring Healthcare Outcomes
P. Li, K. Chow, T. Wong, C. Leung, C. Szeto (2003)
Effects of an Angiotensin-Converting Enzyme Inhibitor on Residual Renal Function in Patients Receiving Peritoneal DialysisAnnals of Internal Medicine, 139
HA Fink, A Ishani, BC Taylor (2012)
Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the US Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline., 156
P. Ruggenenti, A. Perna, G. Remuzzi (2001)
ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy.Journal of the American Society of Nephrology : JASN, 12 12
B. Brenner, M. Cooper, D. Zeeuw, W. Keane, W. Mitch, H. Parving, G. Remuzzi, S. Snapinn, Zhonxin Zhang, S. Shahinfar (2001)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.The New England journal of medicine, 345 12
F. Hou, D. Xie, Xun Zhang, Ping-yan Chen, Wei Zhang, M. Liang, Zhi-jian Guo, Jian-ping Jiang (2007)
Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.Journal of the American Society of Nephrology : JASN, 18 6
Samy Suissa, T. Hutchinson, James Brophy, A. Kezouh (2006)
ACE-inhibitor use and the long-term risk of renal failure in diabetes.Kidney international, 69 5
M. Charlson, P. Pompei, Kathy Ales, C. MacKenzie (1987)
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.Journal of chronic diseases, 40 5
Zheng Zhou, E. Rahme, M. Abrahamowicz, L. Pilote (2005)
Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods.American journal of epidemiology, 162 10
GL Bakris, M Siomos, D Richardson (2000)
ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure., 58
A. Collins, R. Foley, C. Herzog, B. Chavers, D. Gilbertson, A. Ishani, B. Kasiske, Jiannong Liu, L. Mau, Marshall McBean, Anne Murray, W. Peter, Haifeng Guo, Qi Li, Shuling Li, Suying Li, Yi Peng, Yang Qiu, Tricia Roberts, M. Skeans, J. Snyder, C. Solid, Changchun Wang, E. Weinhandl, D. Zaun, Cheryl Arko, Shu‐Cheng Chen, F. Dalleska, F. Daniels, S. Dunning, J. Ebben, Eric Frazier, Christopher Hanzlik, Roger Johnson, Daniel Sheets, Xinyue Wang, B. Forrest, E. Constantini, S. Everson, P. Eggers, L. Agodoa (2010)
Excerpts from the US Renal Data System 2009 Annual Data Report.American journal of kidney diseases : the official journal of the National Kidney Foundation, 55 1 Suppl 1
David Wendler (2012)
Consent for Research With Biological Samples: One-Time General Consent Versus a Gift ModelAnnals of Internal Medicine, 156
G. Laverman, G. Navis, R. Henning, P. Jong, D. Zeeuw (2002)
Dual renin-angiotensin system blockade at optimal doses for proteinuria.Kidney international, 62 3
W. Wilmer, B. Rovin, Christopher Hebert, Sunil Rao, Karen Kumor, L. Hebert (2003)
Management of glomerular proteinuria: a commentary.Journal of the American Society of Nephrology : JASN, 14 12
Shang-Jyh Hwang, Wu-Chang Yang, Ming-Yen Lin, L. Mau, H. Chen (2010)
Impact of the clinical conditions at dialysis initiation on mortality in incident haemodialysis patients: a national cohort study in Taiwan.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 25 8
J. Concato, N. Shah, R. Horwitz (2000)
Randomized, controlled trials, observational studies, and the hierarchy of research designs.The New England journal of medicine, 342 25
ImportanceThe benefit of using a renin-angiotensin-aldosterone system blocker such as an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB) for patients with advanced chronic kidney disease (CKD) remains undetermined. ObjectiveTo assess the effectiveness and safety of ACEI/ARB use for advanced predialysis CKD in patients with hypertension and anemia. DesignProspective cohort study. SettingTaiwan. ParticipantsFrom January 1, 2000, through June 30, 2009, we selected 28 497 hypertensive adult patients with CKD. Serum creatinine levels were greater than 6 mg/dL, hematocrit levels were less than 28%, and patients were treated with erythropoiesis-stimulating agents. InterventionsUsers (n = 14 117) and nonusers (n = 14 380) of ACEIs/ARBs. Main Outcomes and MeasuresWe used Cox proportional hazards regression models to estimate hazard ratios (HRs) for commencement of long-term dialysis and all-cause mortality for ACRI/ARB users vs nonusers. ResultsIn a median follow-up of 7 months, 20 152 patients (70.7%) required long-term dialysis and 5696 (20.0%) died before progression to end-stage renal disease requiring dialysis. Use of ACEIs/ARBs was associated with a lower risk for long-term dialysis (HR, 0.94 [95% CI, 0.91-0.97]) and the composite outcome of long-term dialysis or death (0.94 [0.92-0.97]). The renal benefit of ACEI/ARB use was consistent across most patient subgroups, as was that of ACEI or ARB monotherapy. Compared with nonusers, the ACEI/ARB users had a higher hyperkalemia-associated hospitalization rate, but the risk of predialysis mortality caused by hyperkalemia was not significantly increased (HR, 1.03 [95% CI, 0.92-1.16]; P = .30). Conclusions and RelevancePatients with stable hypertension and advanced CKD who receive therapy with ACEIs/ARBs exhibit an association with lower risk for long-term dialysis or death by 6%. This benefit does not increase the risk of all-cause mortality.
JAMA Internal Medicine – American Medical Association
Published: Mar 1, 2014
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.